Description: An Open Label, Multicenter, First-in-Human, Dose-Escalation Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Mechanism of Action: IgG1 antibody that targets the human TRAIL death receptor (DR5)
Target Patient Population: Expansion cohorts for chondrosarcoma and Ewings sarcoma; in combination with FOLFIRI for pancreatic cancer
Study Design: Drug is given IV every 3 weeks.